0001179110-13-000808.txt : 20130111 0001179110-13-000808.hdr.sgml : 20130111 20130111203201 ACCESSION NUMBER: 0001179110-13-000808 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130110 FILED AS OF DATE: 20130111 DATE AS OF CHANGE: 20130111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fust Matthew K CENTRAL INDEX KEY: 0001397266 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 13526407 MAIL ADDRESS: STREET 1: C/O ONYX PHARMACEUTICALS, INC. STREET 2: 2100 POWELL ST., 12TH FLOOR CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-0000 MAIL ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml FORM 4 - X0306 4 2013-01-10 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001397266 Fust Matthew K C/O ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP & Chief Financial Officer Common Stock 2013-01-10 4 M 0 7112 34.48 A 60400 D Common Stock 2013-01-10 4 S 0 6900 84.41 D 53500 D Common Stock 2013-01-10 4 S 0 3299 85.83 D 50201 D Stock Option (Right to Buy) 34.48 2013-01-10 4 M 0 7112 0.00 D 2019-01-05 Common Stock 7112 63930 D Includes 165 shares purchased through the issuer's ESPP on 12/31/12. Shares sold pursuant to a 10b5-1 plan. Twenty-Five percent of the shares subject to the option vest and become exercisable one year from the date of grant and vest and become exercisable at a rate of 1/48th per month thereafter. The shares were sold at prices ranging from $83.92 to $84.6901. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold at prices ranging from $85.82 to $85.84. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. /s/ Warren DeSouza, Attorney-in-fact 2013-01-14